PuraPharm (HKSE:01498) 3-Year Revenue Growth Rate : -16.70% (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is PuraPharm 3-Year Revenue Growth Rate?

PuraPharm's Revenue per Share for the six months ended in Dec. 2024 was HK$0.44.

During the past 12 months, PuraPharm's average Revenue per Share Growth Rate was -6.10% per year. During the past 3 years, the average Revenue per Share Growth Rate was -16.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was -17.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was -30.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 11 years, the highest 3-Year average Revenue per Share Growth Rate of PuraPharm was 6.30% per year. The lowest was -85.40% per year. And the median was -14.60% per year.

Competitive Comparison of PuraPharm's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, PuraPharm's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PuraPharm's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PuraPharm's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where PuraPharm's 3-Year Revenue Growth Rate falls into.

Save Embed

;

Save Embed

;

PuraPharm 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

PuraPharm (HKSE:01498) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

PuraPharm 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of PuraPharm's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

PuraPharm Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PuraPharm Corporation Ltd (HKSE:01498) » Definitions » 3-Year Revenue Growth Rate

Traded in Other Exchanges

N/A

Address

Wireless Centre, Phase One, Unit 201-207, 2nd Floor, Hong Kong Science Park, Tai Po, New Territories, Hong Kong, HKG

Website

https://www.purapharm.com

PuraPharm Corporation Ltd is a Hong Kong-based Chinese medicine Company. It is engaged in the research and development, production, marketing, and sale of concentrated Chinese medicine granules (CCMG) products marketed under the brand Nong's. The organization provides Chinese medical diagnostic services and operates through several segments: China CCMG, Hong Kong CCMG, Chinese healthcare products, Plantation, and Clinics. The majority of its revenue comes from the Hong Kong CCMG segment, which mainly involves the sale of CCMG products, excluding sales through self-operated clinics in Hong Kong. The group derives revenue from customers located in Hong Kong, Mainland China, and Other countries.

Executives

Chan Yu Ling, Abraham	2101 Beneficial owner
Man Yee Wai, Viola	2202 Interest of your spouse
Fullgold Development Limited	2101 Beneficial owner

PuraPharm Headlines

No Headlines